Key result
Nebivolol exposure (AUC0-∞) was 15 times greater in poor metabolizers than extensive metabolizers, and 3-fold greater in patients with chronic kidney disease.
Why the study?
This review aimed to investigate the pharmacokinetic parameters, drug-drug interactions, and stereoisomers of nebivolol to assist clinicians in optimizing dosage regimens and preventing adverse drug events.
What are the pharmacokinetic parameters and drug-drug interactions of nebivolol?
Population
20 studies comprising plasma concentration-time profile data following oral and IV nebivolol administration
Design
Systematic review
Authors
Loading...
May require nebivolol dose adjustments in poor metabolizers and CKD; extends PK data for personalized dosing.
Systematic Review
What are the pharmacokinetic parameters and drug-drug interactions of nebivolol?
Nebivolol pharmacokinetics are significantly altered by metabolizer status, renal function, obesity, and co-administration with CYP inhibitors, which may require dosage optimization.
Hanif et al. (2023) conducted a systematic review in Hypertension and cardiovascular disorders. Nebivolol was evaluated on Pharmacokinetic parameters (AUC, Cmax, CL, t1/2). Nebivolol exposure (AUC0-∞) was 15 times greater in poor metabolizers than extensive metabolizers, and 3-fold greater in patients with chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: